Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C40H48N2O6.2Cl |
Molecular Weight | 723.725 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].COC1=CC=C2C[C@@H]3C4=C(OC5=CC=C(C[C@H]6C7=C(CC[N+]6(C)C)C=C(OC)C(OC1=C2)=C7)C=C5)C(OC)=C(OC)C=C4CC[N+]3(C)C
InChI
InChIKey=IRPSJVWFSWAZSZ-OIUSMDOTSA-L
InChI=1S/C40H48N2O6.2ClH/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1
Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: neuromuscular Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023284 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | METOCURINE IODIDE Approved UseMetocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.46 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.05 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METOCURINE serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy. | 1999 Jan |
|
Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists. | 2007 Jun |
|
Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. | 2008 Aug |
|
Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor. | 2009 Jan |
|
Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID10954969
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
1732
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
251-461-1
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
71931
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
33335-58-9
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
100000082664
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
C166463
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL1259
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
DBSALT002349
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
SUB07178MIG
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
15BE4G33H2
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY | |||
|
Dimethyltubocurarinium chloride
Created by
admin on Fri Dec 15 14:59:56 GMT 2023 , Edited by admin on Fri Dec 15 14:59:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD